论文部分内容阅读
Tenofovir disoproxil fumarate(TDF)has shown in vitro activity against both HIV and hepatitis B virus(HBV).We retrospectively evaluated the efficacy of TDF(300 mg/d),administered as a part of anti-retroviral therapy,in a large cohort of HIV/HBVcoinfected patients.Sixty-five HIV/HBV-coinfected patients who received TDF for at least 6 months with serum HBV DNA levels above 2.3 log10 copies/mL at TDF initiation and who had stored serum samples before and during TDF therapy were included.Serum HBV DNA was measured on stored samples.The median follow-up period was 12(Q1-Q3:8-17)months.Serum hepatitis B e antigen(HBeAg)was positive in 54 patients(83.1%).Fifty-two patients(80.0%)were receiving lamivudine(LAM)(150 mg twice a day),and 68.8%had documented LAM resistance at baseline.Among HBeAg positive patients,the median reduction from baseline(8.17;Q1-Q3 = 7.30-8.30 log10copies/mL)of serum HBV DNA was 4.56 log10 copies/mL(Q1-Q3 = 3.33-5.55)(P <.0001).In HBeAg-negative patients,serum HBV DNA decline from baseline(4.83;Q1-Q3 = 2.69-6.40 log10 copies/mL)was 2.53 log10 copies/mL(Q1-Q3 = 0.39-4.10).At the end of the study,HBV DNA became undetectable in 29.6%and 81.6%of the HBeAg positive and HBeAg-negative patients,respectively.Serum HBeAg became negative in 4 patients,2 of whom acquired serum hepatitis B e antibody.In conclusion,this retrospective analysis demonstrates the efficacy of TDF against wild-type,presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients.
Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV). We retrospectively evaluated the efficacy of TDF (300 mg / d), administered as a part of anti-retroviral therapy, in a large cohort of HIV / HBV coinfected patients who received TDF for at least 6 months with serum HBV DNA levels above 2.3 log10 copies / mL at TDF initiation and who had stored serum samples before and during TDF therapy were included .Serum HBV DNA was measured on stored samples. The median follow-up period was 12 (Q1-Q3: 8-17) months. Serum hepatitis B e antigen (HBeAg) was positive in 54 patients Patients (80.0%) were receiving lamivudine (LAM) (150 mg twice a day) and 68.8% had documented LAM resistance at baseline. Am HBeAg positive patients, the median reduction from baseline (8.17; Q1-Q3 = 7.30-8.30 log10copies / mL) of serum HBV DNA was 4.56 log10 copies / mL (Q1-Q3 = 3.33-5.55) (P <.0001) .In HBeAg-negative patients, serum HBV DNA dec line from baseline (4.83; Q1-Q3 = 2.69-6.40 log10 copies / mL) was 2.53 log10 copies / mL. At the end of the study, HBV DNA became undetectable in 29.6% and 81.6 % of the HBeAg positive and HBeAg-negative patients, respectively. Serum HBeAg was negative in 4 patients, 2 of patients acquired serum hepatitis B e antibody. in conclusion, this retrospective analysis demonstrates demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients.